- Home
- GLTO vs ADXN Comparison
GLTO vs ADXN Comparison
Compare GLTO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ADXN
- Stock Information
- Founded
- GLTO 2011
- ADXN 2002
- Country
- GLTO Denmark
- ADXN Switzerland
- Employees
- GLTO N/A
- ADXN N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- ADXN Health Care
- Exchange
- GLTO Nasdaq
- ADXN Nasdaq
- Market Cap
- GLTO 9.5M
- ADXN 8.5M
- IPO Year
- GLTO 2020
- ADXN N/A
- Fundamental
- Price
- GLTO $5.81
- ADXN $8.11
- Analyst Decision
- GLTO Buy
- ADXN Strong Buy
- Analyst Count
- GLTO 1
- ADXN 1
- Target Price
- GLTO $10.00
- ADXN $30.00
- AVG Volume (30 Days)
- GLTO 16.5K
- ADXN 58.2K
- Earning Date
- GLTO 11-01-2024
- ADXN 11-22-2024
- Dividend Yield
- GLTO N/A
- ADXN N/A
- EPS Growth
- GLTO N/A
- ADXN N/A
- EPS
- GLTO N/A
- ADXN 0.05
- Revenue
- GLTO N/A
- ADXN $960,641.00
- Revenue This Year
- GLTO N/A
- ADXN N/A
- Revenue Next Year
- GLTO N/A
- ADXN N/A
- P/E Ratio
- GLTO N/A
- ADXN $1.30
- Revenue Growth
- GLTO N/A
- ADXN N/A
- 52 Week Low
- GLTO $5.62
- ADXN $5.00
- 52 Week High
- GLTO $23.50
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- GLTO 25.82
- ADXN 37.43
- Support Level
- GLTO $5.62
- ADXN $7.33
- Resistance Level
- GLTO $6.94
- ADXN $8.25
- Average True Range (ATR)
- GLTO 0.34
- ADXN 0.91
- MACD
- GLTO 0.02
- ADXN -0.29
- Stochastic Oscillator
- GLTO 11.27
- ADXN 17.45
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.